![Elisa Kieback](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Thomas Blankenstein | M | - |
T-Knife GmbH
![]() T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | 6 years |
Thomas Soloway | M | 55 |
T-Knife GmbH
![]() T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | 3 years |
Olivier Litzka | M | 56 |
T-Knife GmbH
![]() T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | - |
Debasish Francois Roychowdhury | M | 63 |
T-Knife GmbH
![]() T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | - |
Detlev Mennerich | M | 55 |
T-Knife GmbH
![]() T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | - |
Alexander Mayweg | M | 49 |
T-Knife GmbH
![]() T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Karin Kleinhans | M | - |
T-Knife GmbH
![]() T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | - |
Holger Specht | M | - |
T-Knife GmbH
![]() T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | - |
Statistics
Country | Connections | % of total |
---|---|---|
Germany | 8 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Elisa Kieback
- Personal Network